Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant Ipilimumab and Nivolumab for High-risk Uveal Melanoma
NCT07501117Phase 1Recruiting
- Start
- Jun 2026
- Primary completion
- Jun 2029
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of nivolumab and ipilimumab in Uveal melanoma (UM). Primary endpoints: Adverse Events at 6 months and Proportion of patients who complete the treatment regimen at 6 months. Started Jun 2026; status: recruiting.
02
Drugs
nivolumabipilimumab
03
Conditions
Uveal melanoma (UM)
Beyond the preview
Go deeper on NCT07501117.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07501117.